S08 ESBRA-NIAAA JOINT SYMPOSIUM ALCOHOLIC LIVER DISEASE: FROM PATHOGENESIS TO TREATMENT
S08.1 INCREASING BURDEN OF ALCOHOLIC LIVER DISEASE 2011
S08.2 RISK FACTORS FOR ALCOHOLIC LIVER DISEASE
S08.3 IMMUNOLOGIC FACTORS IN ALD
S08.5 FIBROGENESIS IN ALCOHOLIC LIVER DISEASE: POSSIBLE THERAPEUTIC OPTIONS
S10 ADDICTIVE BEHAVIOUR: NEW FINDINGS FROM APPETITE REGULATING PEPTIDES, THE HYPOTHALAMUS–PITUITARY–ADRENAL AND THE -GONADAL AXIS
S10.1 THE ROLE OF THE CENTRAL GHRELIN SYSTEM IN REWARD FROM ADDICTIVE DRUGSS10.2 APPETITE REGULATING PEPTIDES: ADIPONECTIN AND RESISTIN IN PATIENTS WITH ALCOHOL DEPENDENCE
S10.3 THE ROLE OF ETHANOL AS A STRESS/HPA AXIS CHALLENGE AND ITS MODULATION OF NEUROSTEROID LEVELS AND NEUROSTEROIDOGENIC ENZYMES IN C57BL/6J AND DBA/2J MICE
S10.4 INTERACTIONS BETWEEN THE HPA- AND THE HPG-AXIS: RELEVANCE FOR CRAVING IN ALCOHOL WITHDRAWAL?
S09 ALCOHOLISM: TRANSCRIPTIONAL/EPIGENETIC ADAPTATIONS IN ANIMAL AND HUMAN BRAIN
S09.1 EPIGENETIC BASIS FOR ANXIETY AND ALCOHOLISMS09.3 FETAL ALCOHOL-INDUCED HYPERMETHYLATION OF PROOPIOMELANOCORTIN GENE IN THE HYPOTHALAMUS TRANSMITS THROUGH GERMLINE
S09.4 EPIGENETIC MECHANISMS IN THE BRAIN OF HUMAN ALCOHOLICS: ADAPTATIONS IN THE OPIOID GENES
S11 ALCOHOL AND THE HEART
S11.1 CLINICAL OVERVIEW OF ALCOHOL EFFECTS ON THE HEARTS11.2 QUANTITATIVE PROTEOMIC ANALYSIS OF ALCOHOLIC CARDIOMYOPATHY
S11.3 MOLECULAR MECHANISM OF ALCOHOL-INDUCED CARDIAC DAMAGE
S12 YOUNG RESEARCHER SYMPOSIUM I: ALCOHOL DEPENDENCE—NEW FINDINGS FROM THE HPA AND THE HPG AXES
S12.1 ROLE OF ADENYLYL CYCLASE TYPE 7 IN HPA AXIS ACTIVATION DURING ETHANOL INTOXICATION, ALCOHOL DEPENDENCE AND DEPRESSIONS12.2 GLUCOCORTICOIDS AND ALCOHOL: THE ROLE OF CORTISOL IN DRINKING BEHAVIOURS, ALCOHOL-RELATED IMPAIRMENT AND TREATMENT EFFICACY
S12.3 THE EFFECT OF NANDROLONE ON ALCOHOL DRINKING IN AA AND WISTAR RATS
S12.4 LIFETIME SEX HORMONE ACTIVITY IN ALCOHOL DEPENDENCE: HUMAN ASSOCIATION STUDIES
S13 NONINVASIVE SCREENING FOR LIVER CIRRHOSIS IN ADDICTIVE PATIENTS
S13.1 IS LIVER STIFFNESS THE NOVEL GOLD STANDARD TO ASSESS LIVER CIRRHOSIS?S13.2 HOW USEFUL ARE SERUM MARKERS TO DETECT LIVER CIRRHOSIS IN ADDICTIVE PATIENTS?
S13.3 SCREENING FOR CIRRHOSIS IN DRUG USERS BY LIVER STIFFNESS MEASUREMENT
S13.4 MEASURING LIVER STIFFNESS IN A COMMUNITY-BASED POPULATION: IS LIVER CIRRHOSIS AN EPIDEMIC PLAQUE?
IDENTIFICATION OF NEUROINFLAMMATION IN THE BRAIN IN VIVO AND IN VITRO AND THERAPEUTIC STRATEGIES TO COMBAT ITS PROGRESSION
S14.1 INFLAMMATORY PROCESSES IN NEURODEGENERATIVE DISEASES
S14.2 IMAGING NEUROINFLAMMATION IN ALCOHOLISM
S14.3 CAN PERIPHERAL MARKERS INDICATE NEUROINFLAMMATION?
S14.4 INFLAMMASOME INDUCTION REGULATES HIPPOCAMPAL NEUROGENESIS AND DEPRESSION
S15 ESBRA/ISBRA JOINT SYMPOSIUM: IMAGING IN ALCOHOL RESEARCH
S15.1 THE ROLE OF FUNCTIONAL NEUROIMAGING IN THE CHOICE OF TREATMENT FOR ALCOHOLICSS15.2 THE DOPAMINE D2/3 RECEPTOR AGONIST RADIOLIGAND [11C]-(+)-PHNO AS A TOOL FOR STUDYING ALCOHOL DEPENDENCE IN HUMANS
S15.3 MULTI-MODALITY IMAGING ASSESSMENT OF ALCOHOLISM'S DAMAGING EFFECT ON BRAIN SYSTEMS AND CIRCUITRY
S16 ALCOHOLIC LIVER DISEASE AND LIVER TRANSPLANTATION
S16.3 RELAPSE OF HARMFUL DRINKING IN LIVER-TRANSPLANTED ALCOHOLICS: RISK STRATIFICATION AND CHALLENGE TO THE 6-MONTH RULES16.4 EARLY LIVER TRANSPLANTATION AS A RESCUE OPTION FOR PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS NON-RESPONSIVE TO THERAPY: A CHANGE OF PARADIGMS?
S17 ALCOHOL AND GABAA RECEPTORS
S17.1 EXTRASYNAPTIC GABAA-RS: PHARMACOLOGY AND REGULATION OF GENE EXPRESSIONS17.2 ROLE OF DELTA SUBUNIT-CONTAINING GABAA-RS IN LOW DOSE ETHANOL ACTIONS ON THE BRAIN
S17.3 THE ROLE OF GABAA-R SUBTYPES IN PUTATIVE ALCOHOL-ANTAGONISTIC EFFECTS OF RO15-4513
S17.4 PROTEIN KINASE C REGULATION OF ETHANOL ACTIONS AT GABAA-R
S18 LESCH TYPOLOGY (LAT): FROM BASIC RESEARCH TO TREATMENT
S18.1 LESCH ALCOHOLISM TYPOLOGY AND TEMPERAMENTS: THEIR ROLE IN ETIOLOGY, COURSE AND TREATMENTS18.2 LAT: NEW RESEARCH DATA
S18.3 PREFRONTAL CORTEX NEUROMODULATION INDUCED BY TRANSCRANIAL DIRECT CURRENT STIMULATION AS A PROMISING APPROACH IN THE TREATMENT OF LESCH'S TYPE IV ALCOHOLISM
S18.5 NEW GENETIC FINDINGS ACCORDING TO LESCH TYPOLOGY
Read Full Abstracts
S19 ESBRA/EASL JOINT SYMPOSIUM: CURRENT THERAPY OF PATIENTS WITH ALCOHOLIC LIVER DISEASE
S19.1 THERAPY OF ALCOHOL ADDICTIONS19.2 THERAPEUTIC APPROACHES TO EXTRAHEPATIC ALCOHOL-ASSOCIATED DISEASES
S19.5 ALCOHOL AND CARCINOGENESIS
S20 ESBRA-APSAAR JOINT SYMPOSIUM: MORPHOLOGICAL AND FUNCTIONAL ALTERATIONS IN THE BRAIN OF ALCOHOLICS
S20.1 PHARMACOKINETICS AND THE BRAIN HEMODYNAMIC AND SUBJECTIVE PERCEPTION EFFECTS OF ACETALDEHYDE IN HETEROZYGOUS ALDH2*1/*2 ALCOHOLICSS20.2 THE POSSIBLE THERAPEUTIC APPROACH FOR AMELIORATION OF ALCOHOL-INDUCED BRAIN DAMAGE
S20.3 CHRONIC ALCOHOL INTAKE CAUSES NEUROINFLAMMATION AND MYELIN ALTERATIONS IN MOUSE BRAIN
S20.4 SYNAPTIC DYSFUNCTION IN THE BRAIN OF THE HUMAN ALCOHOLIC
S20.5 PROLONGED CHANGES IN THE CNS DURING ALCOHOL ABSTINENCE
S21 GENETIC DIFFERENCES AT THE SEROTONIN TRANSPORTER GENE PROMISE A PHARMACOGENETIC APPROACH TO THE USE OF ONDANSETRON WITH AND WITHOUT OTHER AGENTS TO TREAT ALCOHOLISM
S21.3 PHARMACOGENETIC APPROACH AT THE SEROTONIN TRANSPORTER GENE AS A METHOD TO REDUCE SEVERE ALCOHOL CONSUMPTION
S21.4 SEVERITY OF DRINKING AS A PREDICTOR OF EFFICACY OF THE COMBINATION OF ONDANSETRON AND TOPIRAMATE IN RAT MODELS OF ETHANOL CONSUMPTION AND RELAPSE
